Robert Francomano
No más puestos en curso
Fortuna: 33 724 $ al 31/05/2024
Historial de carrera de Robert Francomano
Antiguos cargos conocidos de Robert Francomano.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| SELLAS LIFE SCIENCES GROUP, INC. | Corporate Officer/Principal | 14/03/2022 | 31/03/2024 |
| STEMLINE THERAPEUTICS, INC. | Corporate Officer/Principal | 01/09/2016 | 01/12/2021 |
Formación de Robert Francomano.
| Siena College | Undergraduate Degree |
| University of Albany | Masters Business Admin |
Estadísticas
Internacional
| Estados Unidos | 5 |
Operativa
| Corporate Officer/Principal | 2 |
| Undergraduate Degree | 1 |
| Masters Business Admin | 1 |
Sectorial
| Health Technology | 3 |
| Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| SELLAS LIFE SCIENCES GROUP, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Stemline Therapeutics, Inc.
 Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
- Bolsa de valores
- Insiders
- Robert Francomano
- Experiencia
